Here, we report the sole or joint performance of multiple markers, including the 14-3-3 protein, t-tau and p-tau levels and the p/t ratio, in accurately discriminating between sCJD patients, including pathologically confirmed, clinically definite, and probable cases, and non-CJD patients. The gene discussed is MAPT; the disease is Creutzfeldt Jacob disease.